Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
Idiopathic inflammatory myopathies are a group of systemic autoimmune diseases that involve inflammation of skeletal muscle. The two most common forms are dermatomyositis and polymyositis, the former of which entails a skin component. There are few approved therapeutics available for treatment of th...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2016/9068061 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566973929619456 |
|---|---|
| author | Aarat Patel Georgia Seely Rohit Aggarwal |
| author_facet | Aarat Patel Georgia Seely Rohit Aggarwal |
| author_sort | Aarat Patel |
| collection | DOAJ |
| description | Idiopathic inflammatory myopathies are a group of systemic autoimmune diseases that involve inflammation of skeletal muscle. The two most common forms are dermatomyositis and polymyositis, the former of which entails a skin component. There are few approved therapeutics available for treatment of this group of diseases and the first-line therapy is usually corticosteroid treatment. Considering that a large proportion of patients do not respond to or cannot tolerate corticosteroids, additional treatments are required. There are second-line therapies available, but many patients are also refractory to those options. H.P. Acthar® Gel (repository corticotropin injection [RCI]) is a melanocortin peptide that can induce steroid-dependent effects and steroid-independent effects. Herein, we present a series of cases that involved the use of RCI in the management of dermatomyositis and polymyositis. RCI treatments resulted in improvement in three of four patients, despite failure with previous therapies. The use of RCI did not exacerbate any comorbidity and no significant changes in blood pressure, weight, or glycemic control were observed. Overall, these results are encouraging and suggest that randomized, controlled clinical trials applying RCI to dermatomyositis and polymyositis are warranted. |
| format | Article |
| id | doaj-art-9c973a008c6140baa6dc25ced3fdf25e |
| institution | Kabale University |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-9c973a008c6140baa6dc25ced3fdf25e2025-02-03T01:02:39ZengWileyCase Reports in Rheumatology2090-68892090-68972016-01-01201610.1155/2016/90680619068061Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory MyopathiesAarat Patel0Georgia Seely1Rohit Aggarwal2Arthritis and Osteoporosis Center of Richmond, 9600 Patterson Avenue, Richmond, VA 23229, USADermatology Associates of Virginia, P.C., 10800 Midlothian Turnpike, Suite 309, Richmond, VA 23226, USADivision of Rheumatology and Clinical Immunology, University of Pittsburgh, BST S725, 3500 Terrace Street, Pittsburgh, PA 15217, USAIdiopathic inflammatory myopathies are a group of systemic autoimmune diseases that involve inflammation of skeletal muscle. The two most common forms are dermatomyositis and polymyositis, the former of which entails a skin component. There are few approved therapeutics available for treatment of this group of diseases and the first-line therapy is usually corticosteroid treatment. Considering that a large proportion of patients do not respond to or cannot tolerate corticosteroids, additional treatments are required. There are second-line therapies available, but many patients are also refractory to those options. H.P. Acthar® Gel (repository corticotropin injection [RCI]) is a melanocortin peptide that can induce steroid-dependent effects and steroid-independent effects. Herein, we present a series of cases that involved the use of RCI in the management of dermatomyositis and polymyositis. RCI treatments resulted in improvement in three of four patients, despite failure with previous therapies. The use of RCI did not exacerbate any comorbidity and no significant changes in blood pressure, weight, or glycemic control were observed. Overall, these results are encouraging and suggest that randomized, controlled clinical trials applying RCI to dermatomyositis and polymyositis are warranted.http://dx.doi.org/10.1155/2016/9068061 |
| spellingShingle | Aarat Patel Georgia Seely Rohit Aggarwal Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies Case Reports in Rheumatology |
| title | Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies |
| title_full | Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies |
| title_fullStr | Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies |
| title_full_unstemmed | Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies |
| title_short | Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies |
| title_sort | repository corticotropin injection for treatment of idiopathic inflammatory myopathies |
| url | http://dx.doi.org/10.1155/2016/9068061 |
| work_keys_str_mv | AT aaratpatel repositorycorticotropininjectionfortreatmentofidiopathicinflammatorymyopathies AT georgiaseely repositorycorticotropininjectionfortreatmentofidiopathicinflammatorymyopathies AT rohitaggarwal repositorycorticotropininjectionfortreatmentofidiopathicinflammatorymyopathies |